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according to the BCLC staging classiﬁcation, so this information is
always available anyways. We also agree that the greatest weight
in the ART-score is put on the aspartate aminotransferase (AST)
and not on radiologic response. But this was derived from the
hazard ratio in the multivariate analysis giving the greatest
weight to the rising AST as opposed to other statistically signiﬁ-
cant parameters.
We acknowledge that the authors developed the HAP score
[3], but the HAP score serves a different purpose: it is a prog-
nostic score, which helps to subclassify BCLC-stage B patients
undergoing chemoembolization into different prognostic groups
prior the ﬁrst TACE treatment. In contrast, the ART-score, aims
to detect (1) patients that can tolerate repeated-TACE well and
(2) patients, whose liver function and prognosis would be
harmed by another occlusion of the arterial blood supply to
parts of the liver. So patients might be in a good prognostic
group by the HAP score or by the BCLC stage B subclassiﬁca-
tion at baseline, but a subgroup of these patients may present
with an ART of P2.5 points prior to TACE-2 with subsequent
dismal prognosis in case of retreatment with TACE. On the
other hand, some suboptimal candidates for TACE at baseline
may tolerate repeated TACE quite well as outlined by an ART
score of 0–1.5 points and therefore have a fairly good outcome
with TACE treatment, as detailed in our original ART-score
manuscript.
Regarding the comments by Han and colleagues we would
like to conﬁrm that even if a patient receives 2.5 points in the
ART-score through lack of radiologic response and an increase
in CPS by 1 point after TACE 1, he still is a poor candidate for
further TACE’s. It might be true that he might show a radiologic
response after the second TACE but this will lead to further
deterioration in his liver function and therefore a dismal prognosis
despite radiologic response. This has been clearly shown in our
initial art score manuscript. Therefore the recommendations
by different authors that patients should undergo at least two
TACE-procedures initially – statements made well before the
publication of the art score – cannot be supported anymore.
Regarding the impact of different TACE or TAE techniques, the
authorsmisunderstood themessagewe are giving: itmight be true
that treatment with DC-beads gives a better treatment respond
than cTACE (even though not supported by the published litera-
ture so far [4]), but thiswill be taken into account by the ART-score
anyway through the parameter ‘‘radiologic response’’. Thus, differ-
ent TACE techniques could have an impact on the ART-sore values;
but nevertheless, the ART-score values obtained retain their prog-
nostic signiﬁcance regardless of the technique used.
We disagree with the authors that the response deﬁnition is
different because we did not evaluate patients with complete
response in our initial ART-score manuscript: the deﬁnition was
the same but the inclusion criteria did not allow inclusion of
patients with less than 2 TACE-procedures (which was obviously
necessary to evaluate the impact of repeated TACE’s on outcome,
since patients with complete response do not receive retreatment
with TACE within three months if TACE is applied in a ‘‘on
demand’’ fashion). Patients that had a complete response after
TACE 2 or TACE 3 did not receive further TACE sessions in our
institutions, as outlined very clearly in the methods of our manu-
scripts. So the validation of the ART-score seems to be very robust
but we certainly welcome further evaluation of the ART-score in
different patient populations worldwide, in particular when
performed prospectively.
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Open access under CC BTriple or dual therapy for HCV-1 naive patients?
Optimizing selection toolsWe read with interest the paper by Andriulli et al. [1] about the
identiﬁcation of naïve HCV-1 patients who can be treated with
dual therapy according to baseline and on-treatment parameters.Journal of Hepatology 2
Y-NC-ND license.Important predictive factors of sustained virological response
(SVR) are the IL28B single-nucleotide polymorphisms (SNPs),
however the authors considered only the rs12979860 SNP, for-
getting the more important rs8099917 [2–4]; this is, in our opin-014 vol. 61 j 169–182
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JOURNAL OF HEPATOLOGYReply to ‘‘Triple or dual therapy for HCV-1 naive patients?
Optimizing selection tools’’Editor:
We thank Dr. Boglione and colleagues [1] for their comments on
our recently published paper on the identiﬁcation of naïve HCV-1
patients with chronic hepatitis who may beneﬁt from dual ther-
apy with peg-interferon (PegIFN) and ribavirin (RBV) [2]. To date,
several single nucleotide polymorphisms (SNPs) in the genes
encoding for IFN-k1 (IL29), IFN-k2 (IL28A), IFN-k3 (IL28B), and
IFN-k4 (IFNL4) have been established as predictors of treatmentJournal of Hepatology 20response to PegIFN/RBV [3,4]. Among the identiﬁed SNPs,
rs8099917, rs12979860, and the newly ss469415590 polymor-
phisms have been extensively investigated. Although with con-
ﬂicting results, the question about which of the aforementioned
SNPs, alone or in combination, is (or are) the best baseline mar-
ker(s) of SVR in patients HCV1 is still debated.
Dr. Boglione et al. argue that the contemporary evaluation of
the two SNPs of the IL28B locus may portend greater informationion, not just an academic discussion, because the role of
rs8099917 has been clariﬁed and deepened in several studies
and we think it should be included as best SVR predictor in the
genotype 1 [2–4]. The major impact of rs12979860 has been doc-
umented on the early response [5], while rs8099917 in a recent
meta-analysis evidenced the best predictive effect on the SVR
(OR = 5.171 vs. 4.473) [6]. In fact, the effect of this SNP explains
the higher rate of relapse in patients who achieved both RVR
and ETR with the CC rs12979860 genotype, but with the presence
of a G allele for the rs8099917 SNP [5]. Conversely, patients with-
out the CC genotype for rs12979860 retain good probability to
reach SVR if they have the TT genotype for rs8099917; this issue
could underlie the high rate of SVR in non-CC patients reported
by Andriulli et al. [1] and according with the TT prevalence in
the Italian population. Therefore, we consider it essential to get
both rs12979860 and rs8099917 SNPs as predictors on SVR
and, in more detail, we could select the patients with CC/TT or
CT/TT, but not with CC/TG or CC/GG genotype, for dual therapy.
Another not considered issue in the analysis is the role of ther-
apeutic drug monitoring (TDM) of ribavirin (RBV) as useful early
on treatment predictor of response and toxicity. Ribavirin shows
a wide inter-individual variability in plasma concentrations
(25–30%) and weight-based dose results often inadequate with-
out TDM support [3,4,7]. Interestingly, RBV concentrations are
related both with EVR and SVR [3,4,8,9] or treatment failure in
HCV-1 infected patients, according to different plasma concentra-
tions at different time-points. The optimal therapeutic range of
RBV could maximize the SVR achievement and it should be com-
prised between 2–2.5 mg/L (at week 4 of therapy), according to
the majority of the reviewed studies [10].
In conclusion, we suggest that both IL28B SNPs should be con-
sidered in order to reﬁne the selection of candidate patients for
dual therapy and then the TDM of RBV should be used to improve
the on-treatment management.
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